<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PAMIDRONATE DISODIUM</span><br/>(pa-mi'dro-nate)<br/><span class="topboxtradename">Aredia<br/></span><b>Classifications:</b> <span class="classification">bisphosphonate (regulatory, bone metabolism)</span><br/><b>Prototype: </b>Etidronate<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>30 mg, 60 mg, 90 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>A bone-resorption inhibitor thought to absorb calcium phosphate crystals in bone. May also inhibit osteoclast activity, thus
         contributing to inhibition of bone resorption.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Does not inhibit bone formation or mineralization. Reduces bone turnover and, when used in combination with adequate hydration,
         it increases renal excretion of calcium, and reduces serum calcium concentrations.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypercalcemia of malignancy and Paget's disease, bone metastases in multiple myeloma.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Primary hyperparathyroidism, osteoporosis.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to pamidronate; breast cancer, severe renal disease, hypercalcemia, hypercholesterolemia, polycythemia, pregnancy
         (category X), prostatic cancer, lactation. Safety and effectiveness in children are not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Heart failure, nephrosis or nephrotic syndrome, moderate renal disease; hepatic disease, cholestasis; peripheral edema, prostate
         hypertrophy; chronic kidney failure.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate Hypercalcemia of Malignancy (corrected calcium 1213.5 mg/dL)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 1590 mg infused over 424 h, may repeat in 7 d<br/><br/><span class="indicationtitle">Severe Hypercalcemia of Malignancy (corrected calcium &gt;13.5 mg/dL)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 90 mg infused over 424 h, may repeat in 7 d<br/><br/><span class="indicationtitle">Paget's Disease, Metastases in Multiple Myeloma</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 30 mg once daily for 3 d (90 mg total)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span>  Add 10 mL sterile water for injection to reconstitute the 30, 60, or 90 mg vial to produce concentrations of 3, 6, and 9
                  mg/1 mL, respectively. Withdraw the recommended dose and further dilute with D5W, NS, or 0.45% NaCl.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion: For hypercalcemia of malignancy:</span>  Use 1000 mL of IV solution.  <span class="methodtype">For Paget's disease or osteolytic lesions of multiple myeloma:</span> Use 500 mL of IV solution.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <span class="classification">calcium-containing solutions</span> (including <span class="classification">lactated ringer's</span>). 
               </p>
</td>
</tr>
</table>
<ul>
<li>Refrigerate reconstituted pamidronate solution at 2°8° C (36°46° F); the IV solution may be
            stored at room temperature. Both are stable for 24 h.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Fever with or without rigors</span> generally occurs within 48 h and subsides within 48 h despite continued therapy; <span class="speceff-common">thrombophlebitis at injection site;</span> general malaise lasting for several weeks; transient increase in bone pain. <span class="typehead">Metabolic:</span> <span class="speceff-common">Hypocalcemia</span>. <span class="typehead">GI:</span> Nausea, abdominal pain, <span class="speceff-common">epigastric discomfort</span>. <span class="typehead">CV:</span> Hypertension. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Concurrent use of <b>foscarnet</b> may further decrease serum levels of ionized calcium. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 50% of IV dose is retained in body. <span class="typehead">Onset:</span> 2448 h. <span class="typehead">Peak:</span> 6 d. <span class="typehead">Duration:</span> 2 wk3 mo. <span class="typehead">Distribution:</span> Accumulates in bone; once deposited, remains bound until bone is remodeled. <span class="typehead">Metabolism:</span> Not metabolized. <span class="typehead">Elimination:</span> 50% excreted in urine unchanged. <span class="typehead">Half-Life:</span> 28 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess IV injection site for thrombophlebitis.</li>
<li>Lab tests: Monitor serum calcium and phosphate levels, CBC, and kidney function throughout course of therapy.</li>
<li>Monitor for S&amp;S of hypocalcemia, hypokalemia, hypomagnesemia, and hypophosphatemia.</li>
<li>Monitor for seizures especially in those with a preexisting seizure disorder.</li>
<li>Monitor vital signs. Be aware that drug fever, which may occur with pamidronate use, is self-limiting, usually subsiding in
            48 hours even with continued therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware that transient, self-limiting fever with/without chills may develop.</li>
<li>Generalized malaise, which may last for several weeks following treatment, is an anticipated adverse effect.</li>
<li>Report to physician immediately perioral tingling, numbness, and paresthesia. These are signs of hypocalcemia.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>